RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $36
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an 'Outperform' rating on IDEAYA Biosciences (NASDAQ:IDYA) and raises the price target from $32 to $36.
October 24, 2023 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital maintains an 'Outperform' rating on IDEAYA Biosciences and raises the price target from $32 to $36, which could lead to a positive market reaction.
The raised price target by RBC Capital indicates a positive outlook for IDEAYA Biosciences. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100